Mereo Biopharma Group Plc Statistics
Mereo Biopharma Group Plc (MAH0) Stock Statistics & Valuation Metrics
Total Valuation
Mereo Biopharma Group Plc has a market cap or net worth of EUR 42.59M. The enterprise value is EUR 39.16M.
- Market Cap
- EUR 42.59M
- Enterprise Value
- EUR 39.16M
Share Statistics
Mereo Biopharma Group Plc has 159,690,980 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 159,690,980
- Owned by Insiders
- 0.81%
- Owned by Institutions
- 1.42%
Financial Efficiency
Mereo Biopharma Group Plc’s return on equity (ROE) is -1.02 and return on invested capital (ROIC) is -91.49%.
- Return on Equity (ROE)
- -1.02
- Return on Assets (ROA)
- -0.91
- Return on Invested Capital (ROIC)
- -91.49%
- Return on Capital Employed (ROCE)
- -0.92
- Revenue Per Employee
- 12.82K
- Profits Per Employee
- -1.07M
- Employee Count
- 39
- Asset Turnover
- 0.01
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Mereo Biopharma Group Plc is -1.55. Mereo Biopharma Group Plc’s PEG ratio is -0.04.
- PE Ratio
- -1.55
- PS Ratio
- 59.46
- PB Ratio
- 2.02
- Price to FCF
- -2.18
- Price to Operating Cash Flow
- -2.17
- PEG Ratio
- -0.04
Income Statement
In the last 12 months, Mereo Biopharma Group Plc had revenue of 500.00K and earned -41.88M in profits. Earnings per share was -0.26.
- Revenue
- 500.00K
- Gross Profit
- 367.00K
- Operating Income
- -38.26M
- Pretax Income
- -41.88M
- Net Income
- -41.88M
- EBITDA
- -40.47M
- Earnings Per Share (EPS)
- -0.26
Cash Flow
In the last 12 months, operating cash flow was -22.09M and capital expenditures 297,976, giving a free cash flow of -21.79M billion.
- Operating Cash Flow
- -22.09M
- Free Cash Flow
- -21.79M
- Free Cash Flow per Share
- -0.14
Dividends & Yields
Mereo Biopharma Group Plc pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -45.26%
- Earnings Yield
- -55.48%
Stock Price Statistics
- Beta
- 0.02
- 52-Week Price Change
- -83.43%
- 50-Day Moving Average
- 0.26
- 200-Day Moving Average
- 0.27
- Relative Strength Index (RSI)
- 48.21
- Average Volume (3m)
- 5,460
Important Dates
Mereo Biopharma Group Plc upcoming earnings date is Mar 31, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 09, 2026
- Next Earnings Date
- Mar 31, 2027
- Ex-Dividend Date
- ―
Financial Position
Mereo Biopharma Group Plc as a current ratio of 10.46, with Debt / Equity ratio of 0.49%
- Current Ratio
- 10.46
- Quick Ratio
- 10.46
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.01
- Interest Coverage Ratio
- -150.03
Taxes
In the past 12 months, Mereo Biopharma Group Plc has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Mereo Biopharma Group Plc EV to EBITDA ratio is -0.78, with an EV/FCF ratio of -1.04.
- EV to Sales
- 28.28
- EV to EBITDA
- -0.78
- EV to Free Cash Flow
- -1.04
- EV to Operating Cash Flow
- -1.02
Balance Sheet
Mereo Biopharma Group Plc has EUR 26.10M in cash and marketable securities with EUR 577.00K in debt, giving a net cash position of EUR 25.52M billion.
- Cash & Marketable Securities
- EUR 26.10M
- Total Debt
- EUR 577.00K
- Net Cash
- EUR 25.52M
- Net Cash Per Share
- EUR 0.16
- Tangible Book Value Per Share
- EUR 0.15
Margins
Gross margin is -111.95%, with operating margin of -3797.15%, and net profit margin of -3364.51%.
- Gross Margin
- -111.95%
- Operating Margin
- -3797.15%
- Pretax Margin
- -3435.41%
- Net Profit Margin
- -3364.51%
- EBITDA Margin
- -3642.52%
- EBIT Margin
- -3014.77%
Analyst Forecast
The average price target for Mereo Biopharma Group Plc is EUR 1.78, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- EUR 1.78
- Price Target Upside
- 596.13% Upside
- Analyst Consensus
- Neutral
- Analyst Count
- 4
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 5
- AI Score
- ―
